Abstract. The leukocyte ß1 integrin receptor very late activation antigen-4 (VLA-4) (cY4ßi, CD49d/CD29) binds to vascular cell adhesion molecule-1 (VCAM-1) expressed on cytokine-activated endothelium . A mAb designated 8A2 was identified that stimulated the binding of U937 cells to CHO cells transfected with VCAM-1 cDNA but not endothelial-leukocyte adhesion molecule or CD4 cDNA. mAb 8A2 also rapidly stimulated the adherence of peripheral blood lymphocytes (PBLs) to VCAM-1-transfected CHO cells or recombinant human tumor necrosis factor-treated human umbilical vein endothelial cells. mAb 8A2-stimulated binding of PBL was inhibited by mAbs to VLA-4 or VCAM-1. Surface expression of VLA-4 was not altered T HE emigration of lymphocytes to extravascular sites ofinflammation or immune reaction is mediated by the interaction ofadhesive surface proteins or lymphocytes with ligands on endothelial cells and matrix components . The binding of lymphocyte function-associated antigen-1 (LFA-1) , to intercellular adhesion molecule-1 (ICAM-1) and very late activation antigen-4 (VLA-4) with vascular cell adhesion molecule-1 (VCAM-1, inducible cell adhesion molecule-110 [INCAM-110]) accounts for a major component of lymphocyte binding to cytokine-activated cultured endothelium (7, 16, 32, 34) . LFA-1 (CDlla/CD18) is an integrin receptor of the 01 subfamily that interacts with the endothelial cell ligands ICAM-1(CD54) or ICAM-2, closely related members of the immunoglobulin superfamily (25, 40, 43, 44) . VLA-4 (CD49d/CD29) is an integrin receptor of the ß, subfamily that has recently been shown to bind to both the CS-1 fragment of fibronectin (18, 50) andto vascular cell adhesion molecule-1 (VCAM-1) (12), a cytokine-induced endothelial protein of the immunoglobulin superfamily (28). by mAb 8A2 treatment and monovalent Fab fragments of mAb 8A2 were active. Immunoprecipitation studies reveal that mAb 8A2 recognizes ß1 -subunit (CD29) of integrin receptors . In contrast to mAbs directed to VLA-4 alpha-subunit (tx4, CD49d), mAb 8A2 did not induce homotypic aggregation of PBL . Additionally, mAb 8A2 stimulated adherence of PBL and hematopoietic cell lines to purified matrix components laminin and fibronectin . This binding was blocked by mAbs to the VLA alpha-subunts a6 (CD49f), or «5 (CD49e) and a4 (CD49d), respectively. We conclude that mAb 8A2 modulates the affinity of VLA-4 and other leukocyte ß, integrins, and should prove useful in studying the regulation of ß, integrin function.
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Migration of peripheral blood lymphocyte (PBL) through the subendothelial matrix is dependent at least in part upon other VLA antigens including VLA-5 (CD49e/CD29) and VLA-4 binding to fibronectin and VLA-6 (CD49f/CD29) to laminin (reviewed in 37) .
The adhesive interactions of these receptors and ligands can be regulated at the level of the leukocyte or the endothelial cell. Expression of endothelial cell ICAM-1 is increased by interferon-gamma, lipopolysaccharide, interleukin-1, tumor necrosis factor (TNF) (11, 30) , or phorbol esters (23) , while VCAM-1 is induced by IL-1, TNF, lipopolysaccharide and interleukin-4 (7, 16, 26, 28, 32, 46) . In the case of LFA-1, activation by phorbol ester treatment or cross-linking of T-cell receptor, CD2, or CD3 increases the binding of LFA-1 to ICAM-1 (10, 48) . Phorbol esters also inAntibodies and Reagents Murine mAb 60 .3 which recognizes the 02 subunit (CD18) of the CDl l/CD18 complex (1) was the gift of Dr. Patrick Beatty, Fred Hutchinson Cancer Research Center (Seattle, WA) . Murine mAb 4B9 which recognizes VCAM-1 was generated as previously described (7) . The a4 (CD49d) mAb 163H was the gift of Dr. Michael Gallatin, ICOS Corporation (Seattle, WA) and the a4 (CD49d) mAbs HP 1/l, HP 1/2 and HP 2/1 were the gifts of Dr. Francisco Sanchez-Madrid, Service Immunologia, Hospital de lao Princesa, (Madrid, Spain) (33) . The rat a6 (CD49f) mAb GoH3 was the gift of Drs . Taco Kuijpers and Arnoud Sonnenberg, Central Laboratory of the Netherlands Red Cross Blood Transfusion Service (Amsterdam, The Netherlands) (41, 42) . The anti-ELAM-1 mAb BBII was the gift of Drs. Roy Lobb and Christopher Benjamin, Biogen, Inc . (Cambridge, MA) (3) . The 01 (CD29) murine mAb P4C10, the 012 (CD49b) mAb P4B4, and a3 (CD49c) mAb PIB4 were the gifts of Dr. Elizabeth Wayner, Cytel Corporation (La Jolla, CA) (8) . Murine mAb 4B4 directed to 01 (CD29) was purchased from Coulter Corp. (Hialeah, FL) . Polyclonal antibody A108 which recognizes the VLA-5 fibronectin receptor (a581, CD49e/CD29) and murine monoclonal PID6 which recognizes a5 (CD49e) were purchased from Telios Pharmaceuticals, Inc . (San Diego, CA).
Recombinant human TNF-alpha (rhTNF) was the gift of Dr . Roy Lobb, Biogen Corp . (Cambridge, MA) . Sodium azide, 2-mercapto-ethanol and glutaraldehyde were purchased from Eastman Kodak Co. (Rochester, NY) . Hydrogen peroxide, o-phenylenediamine, NP-40, PMSF, glucose, and 2-deoxyglucose were purchased from Sigma Chemical Co. (St . Louis, MO) .
Leukocytes
Blood was obtained by venipuncture from normal healthy donors under approved protocol . Blood was drawn into polypropylene syringes containing heparin 10 U/ml. The blood was centrifugated over Ficoll-Hypaque (Pharmacia Fine Chemicals, Piscataway, NJ) at 500 g for 40 min at 24°C. The mononuclear layer at the plasma-Ficoll interface was collected by aspiration. Monocytes were removed by two cycles of adherence to serum-coated tissue culture petri dishes (Becton Dickinson & Co ., Lincoln Park, NJ) . The
The Journal of Cell Biology, Volume 116, 1992 suspension of nonadherent cells containing primarily lymphocytes was centrifuged for 6 min at 500 g, resuspended in RPMI 1640 medium with 2% bovine serum (Gibco Laboratories) for use in the adherence assays .
Polymorphonuclear leukocytes were isolated from the Ficoll-RBC interface of the above preparation by 3 % dextran sedimentation and lysis of contaminating red blood cells by hypotonic saline .
Matrix-coated Plates
Purified human fibronectin and murine laminin were purchased from Collaborative Research, Inc. (Bedford, MA) . The matrix components were resuspended in PBS at 15 14g/ml . 200 pl/well were added to 48-well nontreated styrene plates (Costar Corp ., Cambridge, MA) and incubated overnight at 4°C. Wells were rinsed once with PBS, and then incubated for 2 h at room temperature with 0.5 ml of PBS/3 % BSA to block nonspecific binding . Immediately before use, wells were rinsed three times with PBS and 0.2 ml of RPMI containing 5% normal calf serum (Gibco Laboratories) was added .
Adherence Assay
First-or second-passage HUVEs were plated onto gelatin-coated 48-well tissue culture plates (Costar Corp.) and grown to confluency. Designated wells were pretreated for 4 h at 37'C with rhTNF 10 ng/ml . CHO cell transfectants were plated in untreated 48-well tissue culture plates and grown to confluency. Wells were washed once with control medium, RPMI-5 % normal calf serum (NCS) (Gibco Laboratories), and then 0.2 ml of control medium with or without various mAbs was added for 30 min at 37°C. Peripheral blood lymphocytes, U937 and K562 cells were isolated as previously described, suspended in 0.5 ml RPMI, and labeled with 51 Cr for 1 h at 37°C. Cells were washed twice with RPMI medium containing 5 % NCS and resuspended in RPMI medium containing 5 % NCS at a concentration of 1 x 10 6 cells/ml . Labeled cells were aliquoted and treated with mAb 8A2 at various concentrations for 30 min at 37°C. Labeled cells (0.2 ml/ well) were then added to the wells containing monolayers of HUVE or CHO, or matrix components and incubated for 30 min at 37°C. Nonadherent cells were aspirated from each well and the wells were washed once with 0.5 ml/well PBS with 2 % NCS and aspirated dry Adherent cells were lysed with 0.5 ml/well of 1N NH40H, and the lysates were counted in a MicroMedic Gamma Counter (Chicago, IL) for 1 min. Percent adherence was calculated as :
Generation ofmAb 842 BALB/c mice were immunized with hematopoietic cell line U937. Hybridomas were produced by fusion of immunized mouse splenocytes with NS-1 cell line using standard techniques (15) and grown in 96-well tissue culture plates (Costar Corp .) . Hybridoma supernatants were screened by standard enzyme-linked immunoassay (7) for binding to the 2669 melanoma cells, known to express VLA-4 and to bind to VCAM-1 (N . Kovach and J. Harlan, unpublished observation) . Positive hybridomas were then evaluated for effects on adherence of U937 cells to VCAM-1-transfected CHO cells. A hybridoma designated 8A2 was identified by stimulation rather than inhibition of adherence of U937 cells to VCAM-1-transfected CHO cells. It was then serially cloned three times by the method of limiting dilution. mAb SA2 was determined to be IgG1-kappa isotype using a mouse mAb isotyping kit (Amersham Corp., Arlington Heights, IL) .
Ascites was produced by standard technique (21) . Briefly, BALB/c mice were primed with 0.5 ml of pristane (2, 6, 10, 14-tetramethyl-pentadecane ; Sigma Chemical Co .) intraperitoneally 1 wk before intraperitoneal injection of 3 x 106 8A2 hybridoma cells . Ascites was collected after 2-3 wk when significant accumulation was present. mAb 8A2 was purified from ascites by binding to immobilized protein A (Pharmacia Fine Chemicals) as previously described (13) .
Monovalent Fab fragments were generated by incubation of purified mAb 8A2 with papain immobilized on sepharose bead (Pierce Chemical Co., Rockford, IL) for 5 h . Immobilized papain was removed by centrifugation, and the supernatant passed aver an immobilized protein A column . The nonbinding fraction was subjected to 7% SDS-PAGE under nonreducing conditions to confirm purity of the preparation.
Radioimmunoprecipitation
U937 and K562 cells were surface-labeled with 125 1 as previously de-500 % Adherence = 51 CR cpm lysate x 100 51 CR cpm total added scribed (20) . Briefly, 15 ml polypropylene tubes (Becton-Dickinson) were coated with 500 Rg of Iodogen iodination reagent (Pierce Chemical Co.), dried under a stream of nitrogen, and stored dessicated until used . Tubes were rinsed with sample buffer at time of use, and 5 x 101 cells were added with 1 mCi of Na1251, and incubated 20 min at room temperature. Cells were washed three times with PBS, and then lysed for 3 h at 4aC in PBS containing 0.5% NP-40 and 2 mM PMSF Debris and unlysed cells were removed by centrifugation at 12,000 g for 15 min . Cell lysates were precleared by incubation for 1 h with 50 pg nonimmune mouse IgG (Cappel Research Products, Organon Tecknika Corp., West Chester, PA) and 50 Al of rabbit serum, and subsequent incubation with Pansorbin, a 10% suspension of SACI cells coated with protein A (Calbiochem Corp., San Diego, CA) . Lysates were then cleared by centrifugation . After preclearance, aliquots of U937 lysate were incubated for 1 h with 10 iAg mAb 8A2, mAb P4C10, mAb 4B4, polyclonal antibody A108, or mAb 60.3 . Aliquots of labeled precleared K562 lysate were incubated with 10 ug mAb P4C10, mAb PID6, mAb 8A2, or polyclonal A108. Antibody-antigen complexes were removed from the lysates by incubation with 50 Al protein G immobilized to Sepharose beads (Gamma Bind Plus ; Genex Corp., Gaitherburg, MD) . Immobilized protein G-antibody-protein complexes were removed by centrifugation at 20,000 g for 15 min . The beads were washed three times with 0 .1 % NP-40 in PBS, and boiled in SDS-PAGE sample buffer for 10 min . Sepharose beads were pelleted by centrifugation and aliquots of supernatant treated with 5% mercaptoethanol . Immunodepletion was accomplished by three sequential precipitations of the lysates with designated antibodies . Final precipitation of the immunodepleted lysate with mAbs P4C10, 8A2 or 60.3 was performed as described . Samples were then analyzed by 7 % SDS-PAGE and autoradiography.
Fluorescence-activated Cell Sorting
PBLs and neutrophils were isolated as described above . Aliquots of U937, Molt-4, Ramos, and JY were prepared from suspension cultures in exponential growth . Leukocytes, 1 x 106 total per tube, were placed in 5-ml polypropylene tubes (Becton-Dickinson), centrifuged 400 g for 6 min, washed once with HBSS (Gibco Laboratories) and kept at 4aC for all manipulations. 50 pl heat-inactivated adult bovine serum (Hyclone Sterile Systems) was added per tube for 20 min to reduce nonspecific binding. Cells were washed once with HBSS, 50 pl of the first mAb was added at final concentration of 1 :50 for purified mAb and 1 :5 for hybridoma supernatants, and the mixture was incubated for 30 min . In the same experiments, aliquots of U937 cells were pretreated for 30 min at 37'C with 1 /cg/ml of mAb 8A2 Fab fragments and washed twice with HBSS at 4°C before addition of first intact mAb . After reaction with the first mAb, cells were washed three times with cold HBSS, and 50 kl of 1 :25 dilution FITC-labeled goat antimouse Fc-specific second antibody (Tago Corp ., Burlingame, CA) was added . In the case of the rat mAb GoH3 (a6, CD49f), FITC-labeled goat anti-rat IgG was utilized as second antibody (Organon Teknika, Corp ., West Chester, PA) . After incubation for 30 min, cells were washed twice with cold HBSS, and fixed with 250 pl of 1% paraformaldehyde . Samples were analyzed on an Epics Cytofluorimeter (Coulter Corp ., Hialeah, FL) .
Aggregation Assay 50 pl of PBL or U937 cell suspensions, 2 x 10 6 cells/ml, were pipetted per well of a round-bottomed 96-well plate (Costar) . 50 pl of the a4 (CD49d) mAbs HPl/1, HP2/2, or HP2/1 cell supernatants at 1:100 dilution were added to designated wells . 50-,ul dilutions of purified mAb 8A2 in RPMI with 2 % NCS were added to designated wells with final concentrations ranging from 1 to 1,000 ng/ml . Plates were incubated in 5 % C02 at 37°C for up to 18 h, and then visually scored for the presence of aggregation under an inverted microscope.
Results mAb 842 Stimulates U937 Binding to VCAM1-transfected CHO Cells mAb 8A2 was identified by stimulation of U937 cell binding to VCAM-1-transfected but not CD4-or ICAM-1-transfected CHO cells (Fig. 1) . mAb 8A2 induced a fourfold increase in binding of U937 to VCAM-1-transfected CHO cells, and this binding was inhibited by the antiVCAM4 mAb 4B9 (Fig. 1) . Kovach (Table I ). The inhibition of binding was partially reversed by addition of glucose to compete against the 2-DOG. Actinomycin D, a potent inhibitor of RNA synthesis, slightly diminished binding of untreated PBLs to VCAM-1 transfectants, but had no effect on the mAb 8A2-stimulated increase in binding (Table I) . mAb 842 Stimulates PBL Binding to HUVE via VLA-41VCAM1 mAb 8A2 stimulated adherence of PBL to untreated and rhTNF-treated HUVE in a dose-dependent manner in the presence of the 02 (CD18) mAb 60.3 (Fig. 4) . A significant increase in adherence was observed at -50 ng/ml, with maximal stimulation of adherence at 5 p,g/ml . Dose-response curves were essentially parallel between untreated and rhTNF-treated HUVE, but with significantly greater binding to rhTNF-treated HUVE. Enhancement of binding occurred rapidly. Addition of mAb 8A2 to PBL at the beginning ofthe 30-min adherence assay resulted in maximal stimulation of adherence with no further enhancement when PBLs were pretreated with mAb 8A2 for up to 6 h (data not shown) . All studies were subsequently performed with a 30-min coincubation of PBL and mAb 8A2 during the adherence assay.
Since PBL adherence to HUVE involves interaction of hanced binding of PBL to rhTNF-activated HUVE in the presence of 02 (CD18) mAb 60.3 has previously been shown to be due primarily to induction of VCAM-1 on HUVE which interacts with VLA-4 on PBL (7, 12, 16, 32, 34) . In the presence of the CD18 mAb, the a4 (CD49d) mAb 163H inhibited PBL binding to unstimulated and rhTNF-stimulated HUVE.
mAb 8A2 enhanced adherence of PBL to unstimulated HUVE and slightly to rhTNF-stimulated HUVE. The mAb 8A2-induced adherence to unstimulated HUVE and rhTNF- PMN JY Detergent lysates from 125 I-labeled U937 cells were precipitated with polyclonal antibody (A108) directed against a5ß, (CD49e/CD29), the 01 (CD29) mAbs P4C10 or 4B4, the 02 (CD18) mAb 60.3, or mAb 8A2 . Lysates were precleared by three sequential precipitations with various antibodies and then precipitated with the antibody of interest .
Immunoprecipitates were boiled in sample buffer, subjected to SDS-PAGE under nonreducing and reducing conditions, and then autoradiographed . Antibodies directed against ß, (CD29) precipitated a 115-kD band under nonreducing conditions (Fig. 8 A) that migrated to 140 kD under reducing conditions (Fig. 8 B) . mAb 8A2 precipitated a single band that comigrated with the band precipitated by ß, antibodies under both reducing and nonreducing conditions. Preclearance of lysate with the ß,-directed antibodies abolished the precipitation of any band by mAb 8A2 (Fig. 8 B) . Preclearance of lysate with mAb 8A2 ablated precipitation by ß, (CD29)-specific antibodies. Precipitation with the 02 (CD18) mAb 60.3 was not affected by preclearance with a5ß,-specific antibody A108 (Fig. 8 B) . Two nonspecific bands in the 66-97-kD range were observed in all the precipitations including CD18 mAb 60.3. Similar results were obtained when lysates were subjected to SDS-PAGE under nonreducing conditions (data not shown) .
Additional studies were performed using the erythroleukemic cell line K562 which expresses the VLA-5 fibronectin receptor (a5ß1) but not VLA-4 (a4ß1) (19) . Detergent lysates from 'III-labeled K562 cells were precipitated with polyclonal A108 directed against a5ß1 (CD49e/CD29), the as (CD49e) mAb PlD6, the ß, (CD29) P4C10, or mAb 8A2. Analysis by SDS-PAGE and autoradiography revealed that all four antibodies precipitated two bands under nonreducing conditions corresponding to as and 01 that comigrated as a single band under reducing conditions (Fig. 9) .
mAb 842 Stimulates Binding ofHematopoietic Cell Lines and PBL to Purified Matrix Components Fibronectin and Laminin
Having established that mAb 8A2 bound to the common 0 1 subunit of VLA (CD29), we next determined whether mAb 8A2 would modulate the affinity of VLA integrin receptors 504 Figure 7 . mAb 8A2 binds to U937 cells and PBL but not to PMN and JY cells . Binding of isotype-matched control IgG 1 , the 02 (CD18) mAb 60.3, the 01 (CD29) mAb P400, the as (CD49d) mAb 163H, and mAb 8A2 to JY, U937, PBL, and PMN was assessed by flow cytometry as described in Materials and Methods . Similar results were obtained in two additional experiments . PBL and U937 cells also express VLA-6 (CD49f/CD29) by flow cytometry (data not shown) (20) , and bound to murine laminin (Fig . 11) . mAb 8À2-stimulated binding to laminin was inhibited by «6 (CD49f) mAb GoH3 but not a4 (CD49d) mAb 163H (Fig . 11) . Molt-4, K562, and Ramos cells do not express VLA-6 by flow cytometry (data not shown), and did not show significant basal binding or mAb 8A2-stimulated binding to laminin (Fig . 11) .
Discussion
The ß, integrin receptor VLA-4 (a4 ß,, CD49d/CD29) functions in the binding of lymphocytes to extracellular matrix via the CS-1 domain of fibronectin (18, 50) , homotypic aggregation oflymphocytes (2, 6) , and lymphocyte adherence to endothelial cells via VCAM-1 (12, 34) . The interaction of 50 5 Figure 10 . mAb 8A2 stimulates binding of U937, K562, and Molt-4 cells and PBL to purified fibronectin . "Cr-labeled cells were pretreated with medium alone or medium containing mAb 8A2 (5 jig/ ml) . Aliquots of "Cr-labeled cells were also treated with the as (CD49d) mAb 163H, as (CD49e) mAb P1D6 (5 Wg/ml), or both mAbs . 5 'Cr-labeled cells were added to wells containing purified fibronectin as described in Materials and Methods . Percent adherence was determined after a 30-min incubation at 37°C. Values represent means t SEM of triplicate wells in one representative experiment of three separate experiments .
fibronectin was increased by mAb 84,2, and this stimulated binding was inhibited by the as (CD49d) mAb 163H . Binding of PBL to fibronectin was also increased by mAb 8A2, and complete inhibition required both the as (CD49e) mAb PID6 and a4 (CD49d) mAb 163H . Additionally, binding of PBL and U937 cells to laminin was stimulated by mAb 8A2 and inhibited by the a6 (CD49f) mAb GoH3 . These results show that mAb 8A2 also modulates function of VLA-5 and VLA-6 as well as VLA-4 . Figure 11 . mAb 8A2 stimulates binding of PBL and U937 cells, but not K562 or Molt-4 cells, to purified murine laminin . 5'Cr-labeled U937, K562, and Molt-4 cells and PBL were pretreated with medium alone or medium containing mAb 8A2 (5 ug/ml) . Aliquots of each cell type were also treated with the a4 (CD49d) mAb 163H or ab (CD49f) mAb GoH3. 5'Cr-labeled cells were added to wells coated with purified laminin as described in Materials and Methods . Percent adherence was determined after a 30-min incubation at 37°C. Values represent means f SEM of triplicate wells in one representative experiment of three separate experiments .
Our studies indicate that mAb 8A2 recognizes the common beta-subunit (ß,, CD29) of the VLA-4 integrin . Radioimmunoprecipitation studies revealed that a band precipitated by mAb 8A2 that comigrated under nonreducing and reducing conditions with a band precipitated by antibodies to ß,. Immunodepletion studies demonstrated that preclearance of labeled lysates with antibodies to ß, ablated subsequent precipitation by mAb 8A2 . Conversely, preclearance with mAb 8A2 ablated precipitation by antibodies to ß,. Kovach Furthermore, flow cytometry showed that mAb 8A2 bound to cell types known to express ß, and that binding of mAb 8A2 was quantitatively similar to that observed with other ß, (CD29) mAbs (P4C10, 4B4) . Conversely, cells lacking ß, (PMN, JY cells) failed to bind mAb 8A2 . The possibility that mAb 8A2 recognized the a4 subunit (CD49d) of VLA-4 was excluded by the failure of mAb 8A2 to bind to JY cells that express a4 but lack ß, . The beta-subunit which may associate with the a4 subunit in JY cells is unknown . Additionally, mAb 8A2 precipitated bands from K562 cells which express only VLA-5 (a5ß,) that comigrated with bands precipitated by antibodies to a5 or a5ß, . These initial studies do not exclude the possibility that binding of mAb 8A2 may require that the ß, subunit be associated with an appropriate a-subunit . mAb 8A2 could increase VLA-4-dependent binding of U937 or PBL to VCAM-1 by either increasing the surface expression or the avidity of VLA-4. The fact that monovalent Fab fragments of mAb 8A2 induced adherence, but did not increase surface expression of a4 analysis by flow cytometry, indicates that increased binding is not due to increased surface expression of VLA-4 but rather to an increase in avidity.
mAb 8A2 could modulate the affinity of VLA-4 for VCAM-1 and fibronectin, VLA-5 for fibronectin, or VLA-6 for laminin either directly by inducing a conformational change in the receptor upon binding or indirectly by triggering cell activation. O'Toole et al. (29) have reported that monovalent Fab fragments of certain N3-specific mAbs directly stimulated binding of fibrinogen to a,n,ß3 in fixed platelets, presumably lacking any intracellular signaling mechanisms, and to detergent-solubilized receptor in the absence of a membrane microenvironment. Figdor and colleagues have described a mAb (NK1-Ll6) that binds to the a-chain of LFA-1 (CDlla) and stimulates homotypic lymphocyte adhesion (14, 22) . The activity ofthis mAb does not require intracellular signaling, but involves a conformational change in the LFA-1 receptor increasing its affinity for ligand .
Numerous studies have shown that the affinity of integrin receptors for their ligands can be modulated by cell activation. Stimulation of cells by phorbol esters or physiologic agonists have been shown to alter binding avidity of ß, (4, 38, 39, 45, 51) , 02 (5, 49, 52) , and 03 (9, 35, 36) integrin receptors. Cross-linking of other cell surface receptors by mAbs has been shown to modulate avidity of 02 (10, 48) . In particular, mAbs to the a-subunit of VLA-4 (CD49d) have been shown to induce VLA-4-dependent homotypic lymphocyte adhesion (2, 6) by a mechanism requiring energy and intact cytoskeleton (6) . Recently, binding of a mAb to the ß,-subunit (CD29) has been reported to transduce a signal to T cells resulting in elevation ofcAMP (17) , and neuron adhesion to laminin and collagen (27) .
Our initial studies do not determine whether mAb 8A2 acts directly or indirectly. Monovalent Fab fragments of mAb 8A2 were active indicating that cross-linking of the receptor is not required . mAb 8A2-induced binding of PBL to VCAM-1 required a metabolically active cell, since pretreatment with sodium azide and deoxyglucose prevented the increase in binding . These latter results suggest that mAb 8A2 may increase the avidity of VLA-4 by an indirect mechanism requiring active cell metabolism . More detailed studies, 50 however, are required to determine the precise mechanism by which mAb ßA2 alters the affinity ofVLA-4 and other leukocyte ß, integrins. In summary, we have described a mAb to the ß, subunit that rapidly stimulates the binding ofVLA-4 to VCAM-1 and fibronectin, as well as VLA-5 to fibronectin and VLA-6 to laminin . This mAb may prove to be an important tool in understanding the regulation of leukocyte ß, integrin function.
